838 related articles for article (PubMed ID: 20157096)
21. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
22. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
23. Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-A population-based cohort study.
Mittal S; Basu P; Muwonge R; Banerjee D; Ghosh I; Sengupta MM; Das P; Dey P; Mandal R; Panda C; Biswas J; Sankaranarayanan R
Int J Cancer; 2017 Apr; 140(8):1850-1859. PubMed ID: 28108997
[TBL] [Abstract][Full Text] [Related]
24. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease.
Gravitt PE; Kovacic MB; Herrero R; Schiffman M; Bratti C; Hildesheim A; Morales J; Alfaro M; Sherman ME; Wacholder S; Rodriguez AC; Burk RD
Int J Cancer; 2007 Dec; 121(12):2787-93. PubMed ID: 17722112
[TBL] [Abstract][Full Text] [Related]
25. Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project.
Herrero R; Schiffman MH; Bratti C; Hildesheim A; Balmaceda I; Sherman ME; Greenberg M; Cárdenas F; Gómez V; Helgesen K; Morales J; Hutchinson M; Mango L; Alfaro M; Potischman NW; Wacholder S; Swanson C; Brinton LA
Rev Panam Salud Publica; 1997 May; 1(5):362-75. PubMed ID: 9180057
[TBL] [Abstract][Full Text] [Related]
26. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
27. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
[TBL] [Abstract][Full Text] [Related]
28. [Investigation on the prevalence of high risk human papillomavirus and cervical cancer among adult women, in Shenzhen].
DU H; Wu RF; Tang HR; Wu LN; Zhang LJ; Liu ZH; Li J; Li RZ; Wang GP; Zhou YQ; Wang C; Weng LM
Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):799-802. PubMed ID: 22967332
[TBL] [Abstract][Full Text] [Related]
29. The natural history of human papillomavirus infection and cervical intraepithelial neoplasia among young women in the Guanacaste cohort shortly after initiation of sexual life.
Rodriguez AC; Burk R; Herrero R; Hildesheim A; Bratti C; Sherman ME; Solomon D; Guillen D; Alfaro M; Viscidi R; Morales J; Hutchinson M; Wacholder S; Schiffman M
Sex Transm Dis; 2007 Jul; 34(7):494-502. PubMed ID: 17237737
[TBL] [Abstract][Full Text] [Related]
30. Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III.
Terra AP; Murta EF; Maluf PJ; Caballero OL; Brait M; Adad SJ
Tumori; 2007; 93(6):572-9. PubMed ID: 18338492
[TBL] [Abstract][Full Text] [Related]
31. Risk for cervical intraepithelial neoplasia grade 3 or worse in relation to smoking among women with persistent human papillomavirus infection.
Jensen KE; Schmiedel S; Frederiksen K; Norrild B; Iftner T; Kjær SK
Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):1949-55. PubMed ID: 23019238
[TBL] [Abstract][Full Text] [Related]
32. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
33. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe.
Tjalma WA; Fiander A; Reich O; Powell N; Nowakowski AM; Kirschner B; Koiss R; O'Leary J; Joura EA; Rosenlund M; Colau B; Schledermann D; Kukk K; Damaskou V; Repanti M; Vladareanu R; Kolomiets L; Savicheva A; Shipitsyna E; Ordi J; Molijn A; Quint W; Raillard A; Rosillon D; De Souza SC; Jenkins D; Holl K;
Int J Cancer; 2013 Feb; 132(4):854-67. PubMed ID: 22752992
[TBL] [Abstract][Full Text] [Related]
34. Epidemiology of cervical intraepithelial neoplasia: the role of human papillomavirus.
Cox JT
Baillieres Clin Obstet Gynaecol; 1995 Mar; 9(1):1-37. PubMed ID: 7600720
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus-type distribution in women with and without cervical neoplasia in north India.
Bhatla N; Dar L; Rajkumar Patro A; Kumar P; Pati SK; Kriplani A; Gulati A; Broor S; Iyer VK; Mathur S; Shah KV; Gravitt PE
Int J Gynecol Pathol; 2008 Jul; 27(3):426-30. PubMed ID: 18580322
[TBL] [Abstract][Full Text] [Related]
36. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
[TBL] [Abstract][Full Text] [Related]
37. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.
Gonzalez P; Hildesheim A; Herrero R; Katki H; Wacholder S; Porras C; Safaeian M; Jimenez S; Darragh TM; Cortes B; Befano B; Schiffman M; Carvajal L; Palefsky J; Schiller J; Ocampo R; Schussler J; Lowy D; Guillen D; Stoler MH; Quint W; Morales J; Avila C; Rodriguez AC; Kreimer AR;
Vaccine; 2015 Apr; 33(18):2141-51. PubMed ID: 25796338
[TBL] [Abstract][Full Text] [Related]
38. Subsequent risk and presentation of cervical intraepithelial neoplasia (CIN) 3 or cancer after a colposcopic diagnosis of CIN 1 or less.
Pretorius RG; Peterson P; Azizi F; Burchette RJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1260-5. PubMed ID: 17074547
[TBL] [Abstract][Full Text] [Related]
39. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy.
Schneider A; Hoyer H; Lotz B; Leistritza S; Kühne-Heid R; Nindl I; Müller B; Haerting J; Dürst M
Int J Cancer; 2000 Nov; 89(6):529-34. PubMed ID: 11102899
[TBL] [Abstract][Full Text] [Related]
40. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
Bokan T; Ivanus U; Jerman T; Takac I; Arko D
Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
